Den europeiske union - norsk - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - ambrisentan - hypertensjon, pulmonal - antihypertensiva, - volibris is indicated for treatment of pulmonary arterial hypertension (pah) in adult patients of who functional class (fc) ii to iii, including use in combination treatment (see section 5.  efficacy has been shown in idiopathic pah (ipah) and in pah associated with connective tissue disease. volibris is indicated for treatment of pah in adolescents and children (aged 8 to less than 18 years) of who functional class (fc) ii to iii including use in combination treatment. efficacy has been shown in ipah, familial, corrected congenital and in pah associated with connective tissue disease (see section 5.

Den europeiske union - norsk - EMA (European Medicines Agency)

astellas pharma europe b.v. - enzalutamide - prostata neoplasmer - endokrin terapi - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

Den europeiske union - norsk - EMA (European Medicines Agency)

kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - legemidler til behandling av bein sykdommer - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.

Den europeiske union - norsk - EMA (European Medicines Agency)

albireo - odevixibat - cholestasis, intrahepatic - galle- og leverterapi - bylvay is indicated for the treatment of progressive familial intrahepatic cholestasis (pfic) in patients aged 6 months or older (see sections 4. 4 og 5.

Den europeiske union - norsk - EMA (European Medicines Agency)

vetcare oy - medetomidine hydrochloride, vatinoxan hydrochloride - psykoleptika, hypnotika og sedativer - hunder - to provide restraint, sedation and analgesia during conduct of non-invasive, non-painful or mildly painful procedures and examinations intended to last no more than 30 minutes.

Den europeiske union - norsk - EMA (European Medicines Agency)

alnylam netherlands b.v. - vutrisiran sodium - amyloid neuropathies, familial - andre nervesystemet narkotika - treatment of hereditary transthyretin-mediated amyloidosis (hattr amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

Den europeiske union - norsk - EMA (European Medicines Agency)

ferrer internacional s.a. - loxapine - schizophrenia; bipolar disorder - nervesystemet - adasuve er indisert for hurtig kontroll av mild til moderat agitasjon hos voksne pasienter med skizofreni eller bipolar lidelse. pasienter bør få regelmessig behandling umiddelbart etter kontroll av akutte agitasjonssymptomer.

Den europeiske union - norsk - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - orlistat - fedme - antiobesity preparater, ekskl. diettprodukter - alli er indikert for vekttap hos voksne som er overvektige (kroppsmasseindeks, bmi, ≥ 28 kg / m2) og bør tas sammen med en mildt hypokalorisk, fettfattig diett.

Den europeiske union - norsk - EMA (European Medicines Agency)

belpharma s.a. - tasonermin - sarkom - immunostimulants, - beromun er indisert hos voksne som et supplement til kirurgi for senere fjerning av svulsten, slik som å hindre eller forsinke amputasjon, eller i palliativ situasjon, for irresectable av mykt vev sarkom av lemmer, som brukes i kombinasjon med melphalan via mild hyperthermic isolert-lem perfusjon (ilp).

Den europeiske union - norsk - EMA (European Medicines Agency)

novartis europharm limited - rivastigmin - dementia; alzheimer disease; parkinson disease - psychoanaleptics, - symptomatisk behandling av mild til moderat alvorlig alzheimers demens. symptomatisk behandling av mild til moderat alvorlig demens hos pasienter med parkinsons sykdom.